drugset / Trial / NCT00344682

Memantine Augmentation of Antidepressants

NCT00344682 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.

Timeline

Start
2006-06
Primary completion
2011-12
Completion
2011-12

Outcome

Missed primary endpoint

paper Participants receiving memantine did not show a statistically or clinically significant change in MADRS scores compared to placebo, either over the entire study PMID 24229746 ↗

paper β = 0.133, favoring placebo, P = .74 PMID 24229746 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 20 mg Oral

Indications